Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights

Core Points - Rosen Law Firm has initiated a class action lawsuit on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) for the period between March 26, 2025, and November 4, 2025 [1] - The lawsuit alleges that Soleno Therapeutics misled investors regarding its Phase 3 clinical trial for diazoxide choline extended-release tablets (DCCR), particularly concerning safety concerns related to excess fluid retention [1] - The firm claims that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [1] Allegations - The lawsuit accuses Soleno of making false or misleading statements and failing to disclose significant safety concerns related to DCCR [1] - Specific allegations include the downplaying of safety issues and the potential for higher patient discontinuation rates, lower adoption, and adverse regulatory actions [1] - Investors reportedly suffered damages when the true details about DCCR's safety and commercial viability became public [1] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file motions by May 5, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1] - Rosen Law Firm emphasizes its commitment to shareholder rights and has recovered over $1 billion for shareholders since its inception [1]